Galectin Therapeutics Presents New Data on the Treatment of Fatty Liver Disease and Fibrosis at American Association for Study of Liver Diseases 2012

Published: Nov 12, 2012

NORCROSS, Ga.--(BUSINESS WIRE)--Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today presented new preclinical data on the mechanism of action of GR-MD-02 at the American Association for the Study of Liver Disease (AASLD) Annual Meeting in Boston, MA. GR-MD-02 is the Company’s lead galectin inhibitor in development for the treatment of non-alcoholic steatohepatitis (NASH), or fatty liver disease. These new data help to further explain the mechanism of action of GR-MD-02, showing that this galectin inhibitor affects multiple pathways involved with both the prevention and reversal of fibrosis in NASH pathology.

Back to news